Americord Registry Offers Private Cord Blood and Cord Tissue Banking at Half the Price of Its Competitors
Americord CEO explains how the company delivers cord blood and cord tissue banking at significantly lower prices than ViaCord or CBR
New York, NY (PRWEB) April 02, 2012
Americord Registry, a leader in the advancement of cord blood, cord tissue and placenta banking, announced today it is making cord blood and cord tissue banking available at prices approximately 50% lower than those of other cord blood industry leaders, including ViaCord and CBR. A detailed comparison of the costs for cord blood banking and the costs for cord tissue banking for Americord, ViaCord and CBR can be found at cordadvantage.com/product-comparison.
“Many of our competitors spend approximately 50% of their revenue on marketing and sales expenses,” said Martin Smithmyer, President and CEO of Americord. “We believe this represents $50-100 million in annual expenses for just one of our competitors.” Such expenses typically include nationwide pharmaceutical sales and marketing teams, magazine and television advertisements, entertainment for doctors, and in some cases, direct compensation to doctors and hospitals to promote a particular cord blood bank’s products.
“In contrast to our competitors,” said Mr. Smithmyer, “Americord Registry spends closer to just 5% of our revenue on sales and marketing, and we pass the savings along to our clients. Our goal is to make high quality cord blood and cord tissue banking as affordable as possible. To achieve that goal, we rely primarily on grass roots marketing and word of mouth and avoid sales and marketing expenses unless they directly benefit clients.”
Americord is committed to offering the highest quality cord blood and cord tissue banking in the industry. The company’s laboratories are CLIA Certified, accredited by the AABB and comply with all federal and state guidelines and applicable licenses, following the best practices for cord blood banking industry. Americord’s Medical Director, Dr. Robert Dracker, was the original Executive Medical Director at ViaCord and is considered to be one of the fathers of the industry. Dr. Dracker sits on the Pediatrics Advisory Panel for the FDA and was one of the authors of the cord blood banking guidelines for New York State.
“Americord was founded in part to reduce the limitations that are inherent to the cord blood banking industry, and cost is among those limitations for too many families,” said Dr. Dracker. “By offering cord blood and cord tissue banking at 50% of the typical cost, we are making this valuable resource available to many more families.”
For more information about Americord Registry, or to speak with Mr. Smithmyer, please email pr(at)cordadvantage(dot)com.
About Americord Registry
Americord Registry, a leader in the advancement of cord blood, cord tissue and placenta banking, collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 75 blood diseases such as sickle cell anemia and leukemia.
Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company’s laboratories are CLIA Certified, accredited by the AABB and comply with all federal and state guidelines and applicable licenses. Americord is headquartered in New York, NY. You may visit Americord Registry’s website at cordadvantage.com for more information.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/4/prweb9347913.htm